Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares
Journal of Clinical Investigation | July 1, 2025 | Volume: 135 | Issue: 17 | Pages: No page available
10.1172/jci188530
| PMID 40591420